Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
-
BUSINESS Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
-
COMMENTARY Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
-
ORGANIZATION JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
June 20, 2025
-
BUSINESS Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
-
BUSINESS Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
-
ORGANIZATION JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
-
REGULATORY Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
-
ORGANIZATION Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
-
BUSINESS AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
-
BUSINESS Prashant Nikam to Take Over Helm of MSD Japan
June 12, 2025
-
BUSINESS Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
-
BUSINESS Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
-
REGULATORY LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
-
REGULATORY Honebuto Draft Urges Promotion of Drug Innovation, but Spells Out CEA Expansion Too
June 9, 2025
-
BUSINESS Takeda Rolls Out AI Tool to Guide “Next Best Action” in Sales
June 6, 2025
-
ORGANIZATION New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
June 5, 2025
-
REGULATORY Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
June 4, 2025
-
ORGANIZATION New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
June 3, 2025
-
REGULATORY New Skipper of PMDA’s Review Center Wears Multiple Hats to Push Fight against Drug Loss
June 2, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…